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etc. The unit of measurement was cost per successful treatment. Differences in costs 
and efﬁ cacy rates were analyzed by the appropriate statistical tools. The study was 
performed from a government’s perspective. RESULTS: A total of 44 patients were 
evenly randomised to receive LNG-IUS treatment and TBEA and evaluation was
performed 1 year after treatment. Of these, 18 patients from the LNG-IUS group 
completed the study with 3 dropouts. Ten achieved menorrhagic control and 5 had
to be converted to other therapies. In patients receiving TBEA therapy, 7 dropped
out and 15 were deemed successful. The overall cost of treatment for LNG-IUS and 
TBEA groups was HKD140,000 (USD18,000; 1USD  7.8HKD) and HKD430,000 
(USD55,000) respectively. The average cost per successful treatment per patient was 
therefore HKD14,000 (USD1,800) and HKD28,600 (USD3,660) for the LNG-IUS and 
TBEA patients respectively. CONCLUSIONS: From this small group of patients
enrolled in a clinical trial to assess the outcomes of LNG-IUS and TBEA, it appears 
that the LNG-IUS therapy is more cost-effective. The major cost drivers appear to be 
the procedural and hospitalization costs arising from TBEA.
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OBJECTIVES: To evaluate the costs and effectiveness of the conventional drug treat-
ment with clomiphene citrate versus anastrozole in the induction of the ovulation in 
infertile adult patients attending a Mexican public hospital. METHODS: A prospec-
tive and descriptive clinical pilot study was conducted in a Mexican public hospital 
“La Raza” of the Mexican Social Security Institute (IMSS). Thirty adult patients with
infertility due to anovulation were recruited and grouped into two groups. Group A
was treated with clomiphene citrate and group B with anastrozole for 6 months. A 
systematic scientiﬁ c review of the published literature related with the two drugs was 
done, in order to gather the drug efﬁ cacy and adverse effects probabilities. The drug 
efﬁ cacies gathered in the Mexican clinical pilot study and the efﬁ cacy data from the
literature review were analyzed by means of meta-analysis. The direct medical and 
non direct medical costs as well as the indirect costs were assessed using a micro-
costing process. Using the Mexican women epidemiological data a hypothetic popula-
tion of 10000 was considered. A time horizon of one year was estimated. The
Markov-Montecarlo model-computarized TreeAge Program was used in order to 
evaluate the cost-effectiveness (CE) ratio. The discount rate, incremental and marginal
analyses were done. RESULTS: The meta-analysis odds ratio was 0.85 for the ovula-
tion induction and 1.46 for pregnancy. The most CE treatment was clomiphene citrate
with a ratio of $173 dollars/QALY versus $192 of anastrozole. The result of the
incremental analysis was $18 dollars/QALY. CONCLUSIONS: The conventional drug
treatment (clomiphene) is the most cost/effective for the present study population. 
Further investigations are needed in order to assess the costs of adverse events in order
to obtain conclusive data.
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OBJECTIVES: To estimate the expected health beneﬁ ts, costs and incremental cost-
effectiveness ratio of routine vaccination with the new 10-valent pneumococcal non-
typeable haemophilus inﬂ uenzae protein-D conjugate vaccine (PHiD-CV) compared 
with no vaccination and the currently available 7-valent pneumococcal conjugate
vaccine (PCV-7) in Sweden. METHODS: A cross-sectional population model was used 
to estimate the impact of vaccination over 1-year at vaccine steady-state and to
perform an incremental cost-effectiveness analysis, comparing 3 different vaccination
strategies. The base-case analysis was performed from a societal perspective, using a
3 dose (2  1) vaccination schedule. The effects of herd-protection, serotype replace-
ment and serotype cross-protection were calculated separately. The main outcomes 
were measured by reduction in the disease burden, costs, QALYs and incremental
cost-effectiveness ratio (ICER) per QALY gained. Sensitivity analyses were performed 
to evaluate the robustness of the model. RESULTS: Preliminary results indicate that
PHiD-CV could prevent a considerable number of pneumococcal infections- particu-
larly acute otitis media. Annual health care costs (vaccine costs excluded) and indirect
costs with PHiD-CV are estimated at 10% and 12% lower than with the no vaccina-
tion strategy, and 6% and 7 % lower, than with PCV-7. Expected QALY gain from 
vaccination is twofold compared with PCV-7. At price-parity, health beneﬁ ts of vac-
cination can be achieved with a “low cost” per QALY (€10, 000) compared with no
vaccination and the estimated mean differences in cost and QALYs indicate that PHiD-
CV dominates PCV-7. PHiD-CV was predicted to prevent 18,000 more antibiotic 
prescriptions than PCV-7. Sensitivity analyses show that the results are most sensitive
to changes in parameters related to AOM. CONCLUSIONS: Our preliminary results 
indicate that the health beneﬁ ts of vaccination with PHiD-CV compared with no 
vaccination and PCV-7 can be achieved within a “low cost” per QALY gained, accord-
ing to the Swedish National Board of Health and Welfare’s ranking.
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EXPANDED NEWBORN SCREENING IN TEXAS: 
A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODELING
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OBJECTIVES: Texas House Bill 790 resulted in the expansion of the newborn
screening panel from 7 to 27 disorders. The objective of this study was to estimate
the incremental cost-effectiveness of the expanded newborn screening program (27 
disorders) compared to the previous standard screening (7 disorders) in Texas.
METHODS: A Markov model (for a hypothetical cohort of Texas births in 2007)
was constructed to compare life-time costs and QALYs between the expanded
newborn screening and pre-expansion newborn screening. Estimates of costs, proba-
bilities of sequelae, and utilities for disorder categories were obtained from Texas 
statistics, the literature, and expert opinion. A baseline discount rate of 3% was used 
for both costs and QALYs, with a range of 0% to 5%. Analyses were conducted from
a payer’s perspective, so only direct medical cost estimates were included. RESULTS:
The life-time incremental cost-effectiveness ratio (ICER) for expanded versus pre-
expansion screening was about $11,000/QALY. Probabilistic sensitivity analysis using
key variables showed that results ranged from about $9,500 to $13,000 /QALY. This 
range is well below the commonly cited willingness to pay threshold of $50,000/QALY. 
CONCLUSIONS: Expanded newborn screening does result in additional expense to 
the payer but also improves patient outcomes by preventing avoidable morbidity and
mortality. The screened population beneﬁ ts from greater QALYs as compared to the 
unscreened population. Overall, expanded newborn screening in Texas was estimated 
to be a cost-effective option as compared to unexpanded newborn screening.
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OBJECTIVES: Recent estimates of cost of otitis media (OM) among children in the 
United States are not available. The objective of this study was to estimate the incre-
mental direct medical expenditures of treating OM among children in the United
States. METHODS: Retrospective analysis was conducted using the 2005 Medical 
Expenditure Panel Survey (MEPS) data. Among all children (age  18 years; n  9691), 
children with OM were identiﬁ ed using International Classiﬁ cation of Diseases (ICD)-
9 diagnosis codes 381 or 382 for OM. Incremental total expenditures associated with
OM was estimated using a regression model adjusting for age, gender, race, ethnicity,
education, geographic region, insurance status and number of medications used (proxy
for comorbidity). Given the skewed distribution of expenditure variables, multiple 
model speciﬁ cations including ordinary least squares regression, generalized linear 
model (GLM) with Poisson, gamma and negative binomial variance functions were 
evaluated. RESULTS: The prevalence of OM among children in the US was estimated
at 11.08%, i.e., 8.15 million persons (95% CI: 10.28% to 11.94%). A majority of 
children with OM were male (52.3%), white (85.7%), and insured (97.3%) with mean 
age of 5.2 o 0.16 years and education of 1.0 o 0.09 years. In unadjusted analysis 
among patients with OM, inpatient visits was the largest proportion of the total
expenditures at $708.97 (SE: $384.25), followed by physician ofﬁ ce visits at $646.35
(SE: 48.07), outpatient visits at $370.88 (SE: $167.97), and prescription medications 
at $348.39 (SE: $122.26). After controlling for covariates, children with OM had
25% higher total expenditures than those without OM (Estimate: 1.25; p  0.024). 
The annual adjusted mean incremental total expenditure associated with OM was 
$245.6 (SE: $117.4; p  0.036) per person. CONCLUSIONS: Given the prevalence
of OM in children and its associated incremental expenditures, the annual direct
medical expenditure for treating OM in children is estimated at approximately $2 
billion in 2007 US dollars.
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OBJECTIVES: To describe the drivers of health care costs among commercially
insured women in the United States with a diagnosis of Hypoactive Sexual Desire 
Disorder (HSDD). METHODS: The Thomson Reuters Marketscan Claims Database
was used to identify women aged 18–64 who received a diagnosis of HSDD from 
january 1, 1998-September 30, 2006. A control group of women with no indication
of any sexual dysfunction was matched 3:1 to HSDD cases based on age, health plan 
and enrollment period. Controls were assigned the index date of their matched case.
Total health care expenditures were evaluated for the one-year prior to and following
the index date and were categorized by type of service (inpatient, outpatient medical, 
outpatient other, prescription). Outpatient medical services included ofﬁ ce visits, labo-
ratory and outpatient procedures; radiology and behavioral health services were cate-
gorized as “outpatient other”. RESULTS: A total of 2870 women were coded with 
an HSDD diagnosis and matched to 8610 controls. In the year prior to index, the 
HSDD group incurred total health care costs that were $1146 higher (p  0.001); in 
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the year following index the same HSDD group incurred total health care costs that
were $897 (p  0.001) higher. Drivers of increased health care costs in the year prior
to index diagnosis included inpatient services (21.1% of the cost difference), outpa-
tient medical services (45.1% of the difference) and prescription medications (17.3%).
During the year following index diagnosis, outpatient medical services accounted for 
53.4% of the cost difference, while prescription medications accounted for 33.3%. 
CONCLUSIONS: Women with HSDD utilize signiﬁ cantly more health care services
and incur higher overall costs before and after diagnosis compared with women
without a diagnosis of sexual dysfunction. While outpatient medical services were the 
largest component of overall health care costs for patients with HSDD, prescription 
medication costs were also signiﬁ cantly higher than matched controls.
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OBJECTIVES: To determine the annual direct cost of treatment of vaginitis in Turkey.
METHODS: A consensus panel approach was implemented in order to deﬁ ne the 
vaginitis management pattern and relevant resource utilization. The panel consisted
of 11 gynecologists, afﬁ liated with the existing patterns of outpatient health care set-
tings. Cost analysis was based on the estimation of 1 year direct cost of treatment,
based on 2008 fees and prices, expressed in dollars. RESULTS: Total cost of vaginitis 
treatment was found to be $81.6 per patient. This cost covered partner expenditures. 
The disbursement included outpatient clinic fees and pharmacotherapy. The labora-
tory tests were included in the outpatient clinic fees according to new Social Security
Institution (SSI) regulations. CONCLUSIONS: Altough the prevalence and causes of 
vaginitis are uncertain, in part because the condition is so often self-diagnosed and
self-treated, women often seek medical care for vaginal complaints. SSI may have to
reimburse vaginitis treatment more than once for a woman in a year. Therefore, the
SSI should know the cost of vaginitis treatment in order to make a budget plan among
other treatments.
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OBJECTIVES: To compare international estimates for direct and indirect cost of falls
among older adults. We compared both the total cost of falls and the mean cost per
individual fall. METHODS: We conducted a systematic review of peer reviewed
journal articles reporting estimates for the cost of falls in older adults. We searched 
for papers published between 1945 and July 2008 in MEDLINE, PUBMED, EMBASE,
CINAHL, Cochrane Collaboration and NHS EED and identiﬁ ed papers that included
a cost analysis of falls in older adults. We report cost of falls in the manuscripts’ cur-
rency and in US dollars at 2008 prices, cost items measured, perspective, time horizon 
and sensitivity analysis. We assessed the quality of the studies using a selection of 
questions from Drummond’s Checklist. RESULTS: Twenty-two studies met our inclu-
sion criteria and these included 11 studies from the United States, three from Australia, 
four from Europe and two each from New Zealand and the UK. There were distinct 
variations across studies with respect to: viewpoint of the analysis, deﬁ nition of falls, 
identiﬁ cation of all important and relevant cost items and time horizon. Our quality 
assessment indicated that only two studies reported a sensitivity analysis and only four
studies identiﬁ ed the viewpoint of their economic analysis. A prospective cohort study 
indicated the total one-year cost of all fall related injuries in 1995 was US $88.36 
billion (at 2008 prices). CONCLUSIONS: The cost of falls depended largely on the 
time horizon over which costs were collected, cost items collected and deﬁ nition of 
falls. To accurately compare costs among countries, we need a consensus on deﬁ nition 
of fall related outcome measures and cost items.
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AN INVESTIGATION OF THE EFFECTS OF GENDER, RACE, AGE, 
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Perry JD
University of Louisville, Louisville, KY, USA
OBJECTIVES: Pharyngitis is a disease that commonly affects patients from various
ages, genders, and ethnicities. This investigation will serve as an exploratory analysis
of basic pediatric inpatient descriptors, and their relationships with respect to hospi-
talization charges, length of hospitalization, and the contraction of Pharyngitis.
METHODS: In this study, length of hospitalization and hospitalization charges are 
analyzed with respect to patient age, gender, and race. Logistic and linear regressions
are included to show relationships among independent variables, descriptive variables, 
and the contraction of Pharyngitis. The Statistical Analysis Software (SAS), Enterprise
Guide version 4.0, was utilized in the data analysis. The data are from the 2005
National Inpatient Sample and contained 4169 patients with Pharyngitis and a control
group of 4200 patients. RESULTS: It was shown that on average, White, male, Phar-
yngitic patients 0–3 years old pay the least in hospitalization charges while female 
patients of Asian/Paciﬁ c Islander descent 12–15 years old pay the most in hospitaliza-
tion charges. White, female patients 0–7 years old have the shortest hospitalization
periods while male patients of Native American descent 12–18 years old have the
longest average hospital visits. In total, several variables, including speciﬁ c procedures
and diagnoses, such as Volume Depletion and Fever, are seen as statistically signiﬁ cant
in determining the likelihood of a patient contracting Pharyngitis. Additional results 
were derived from a linear regression, which contains analysis speciﬁ c to length of 
hospitalization and hospitalization charges. CONCLUSIONS: This investigation pro-
vides only a general overview of the statistical relationships contained within a data 
set of pediatric inpatients primarily afﬂ icted with the disease, Pharyngitis. Because of 
the nature of the disease, it should be noted that further investigations should be
conducted to verify any relationships found to be statistically signiﬁ cant.
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OBJECTIVES: Infertility is a vital problem for men and woman in Turkey. It decreases 
the quality of life more than many chronic diseases. The infertility treatment is reim-
bursed by the government, only twice in a life-time and only if you are a woman 
younger than 39 years old. Infertility treatment can be considerably long, and many
times, the couples need to try more than twice. The government reimburses €656 
(1240 YTL) for each treatment. The objective of this study was to calculate the cost 
of infertility treatment at a University Hospital. METHODS: An expert panel com-
posed of obstetricians in Osman Gazi University developed an infertility clinical pro-
tocol for this particular university. This protocol was used to calculate the cost of an
infertility intervention. A third- party payer perspective to estimate cost of this inter-
vention was chosen. Therefore, to estimate the total cost of an infertility intervention, 
the ofﬁ cial price lists established by the Social Security Organization was used. 
RESULTS: Specialists developed three clinical pathways; antagonist protocol, short
and long protocol. Total cost of the antagonist protocol was 1079 Euro, for the short 
protocol this was €1117, and the long protocol €1059. If the couple had to try all 3
protocols, they had to pay €3255, and the government reimbursed only 1312 Euro. 
This meant that the couple had to pay €1943. CONCLUSIONS: The Social Security
Organization extended the prospective payment system (ﬁ xed prices for treatment) 
coverage for hospital services including fertility treatments, in 2003. We found out 
that, ﬁ xed prices determined by SSO do not reﬂ ect actual costs of the services. Due 
to the fact that the cost of services delivered in university hospitals are higher than
other hospitals, university hospitals should develop cost saving strategies to provide 
fertility treatment services.
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OBJECTIVES: The increasing rate of multiple pregnancies, which are associated with
greater health resource use, has been attributed to the broad availability and use of 
assistive reproductive technologies (ARTs). The advocate of publicly funding ARTs
argues that, if publicly funded, the government could consider mandating the number
of embryos transferred per IVF cycle so as to contain the health care cost. The study
was to investigate the association between multiple gestations and low birth weight 
(LBW) infants and to explore the impact on health resource utilization and costs.
METHODS: The population cohort comprised mothers and infants born between 
April 1, 2004 and March 31, 2005 in Alberta, Canada. The study considered costs
and resource utilization from birth to 1 year for infants and from pregnancy to 3 
months post partum for mothers. Information related to hospital costs was collected 
from Alberta hospital inpatient database, while that related to physician services from
the Alberta Health Care Insurance Plan. A logistic regression was employed to deter-
mine the likelihood that twins and higher order multiples (HOM) was born LBW, 
compared with singletons. Linear regressions were used to estimate the impact of 
multiple births and LBW on resource utilization and costs. RESULTS: A cohort of 
36,158 mothers and 36,767 infants were included in the study. The logistic regression 
indicated that, compared to singletons, twins and HOM were 43.8% and 90% more 
likely to be born LBW respectively, while HOM were 46.2% more likely to be born
LBW in comparison with twins. The mean total cost of LBW twins and LBW HOM 
were respectively, 5.88 ($14,253 vs. $2,425) and eight times ($19,435 vs. $2,425)
greater than that of NBW singletons. CONCLUSIONS: This study suggested that 
multiple births were associated with higher likelihood of being born LBW and conse-
quently resulted in more resource utilization.
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OBJECTIVES: To compare medication adherence for patients new to 90-day supply
prescriptions under a new pharmacy beneﬁ t where pricing is equivalent, allowing 
